###### Significance of this study

What is already known about this subject?
=========================================

-   Evidence from a meta-analysis of seven randomized controlled trials indicates that pioglitazone exposure did not change the risk of death from any cause in patients with type 2 diabetes, pre-diabetes or insulin resistance. These trials were primary designed to study cardiovascular and composite outcomes.

-   Previous secondary analyses of data from the original pan-European and other large retrospective cohort studies have demonstrated a statistically significant reduction in the risk of all-cause mortality with pioglitazone use.

-   A range of exploratory studies have demonstrated that thiazolidinediones such as pioglitazone may have patient benefits beyond diabetes control and reduction of cardiovascular risk.

What are the new findings?
==========================

-   This exploratory extension of the pan-European, observational, large cohort study suggests that exposure to pioglitazone compared with an alternative treatment decision at a similar stage of disease progression is associated with a statistically significant 42% and 37% reduction in cardiovascular and non-cardiovascular mortality, respectively.

How might these results change the focus of research or clinical practice?
==========================================================================

-   The suggestion of potentially broader benefits of pioglitazone supports its safe and effective use. Lack of agreement between randomized control trials and observational studies is likely to be due to reduced statistical power in the former and unresolved bias in the latter. Findings from this study can be used to inform study design for further research evaluating the association of pioglitazone use with specific long-term diagnostic and mortality outcomes.

Introduction {#s1}
============

Diabetes mellitus is one of the most common chronic diseases worldwide, and its global prevalence continues to rise due to the aging population, obesity, urbanization and changes associated with lifestyle such as physical inactivity. The increased risk of cardiovascular (CV) disease among patients with type 2 diabetes mellitus (T2DM) has been studied for many years and is well described in the literature. It is estimated that CV disease is responsible for some 70% of all mortality among patients with T2DM,[@R1] and newly diagnosed adult diabetic patients have 5--10 years shorter life expectancy than the general population.[@R2]

We recently published results from a pan-European multidatabase study indicating no evidence of an association between pioglitazone use and bladder cancer risk[@R4] when compared with other antidiabetic drugs used in patients with T2DM. Further, in the same study, we found a statistically significant 33% reduction in all-cause mortality associated with pioglitazone use.[@R5] This evidence of a reduction in risk of mortality supports other observational studies,[@R6] though findings from a meta-analysis of seven trials demonstrate no significant difference in the risk of mortality with use of pioglitazone in patients with insulin resistance, pre-diabetes and T2DM compared with trial comparators.[@R8]

A recent review has summarized the findings of a large number of preclinical, clinical and observational studies that point to an overall beneficial effect of pioglitazone on CV disease in patients with T2DM and possible pleiotropic benefits.[@R9] We report the findings of post-hoc analyses following from our original study findings of a reduced all-cause mortality associated with pioglitazone use, focusing on cause-specific mortality among patients with T2DM using data from Finland (FIN), Sweden (SWE) and the UK.

Methods {#s2}
=======

Study design and setting {#s2a}
------------------------

This exploratory linked database cohort analysis used three of the six non-overlapping datasets included in the bladder cancer and all-cause mortality analyses[@R4]: FIN, SWE and the UK linked GP hospital dataset (UK GP-HOSP). Death registration data were not available for the remaining datasets. Data from the Clinical Practice Research Datalink (CPRD) were used in the UK.

Data sources and outcome definition {#s2b}
-----------------------------------

Drug exposure measures were generated from prescription data in the UK and dispensing data in FIN and SWE.

Cause-specific mortality was measured using the underlying cause of death field in linked national death registries in all countries. The following CV-related causes of death were classified using International Classification of Diseases, Tenth Revision (ICD-10) codes: myocardial infarction (MI), stroke, sudden death, congestive heart failure (CHF) or cardiogenic shock, renovascular disease, peripheral vascular disease, arrhythmia and other CV (aortic aneurysm, other) (see online [supplementary appendix table S1](#SP1){ref-type="supplementary-material"}). All other causes of death were classified as non-CV. All causes of death are summarized by ICD-10 code chapter. Additional data from cancer registries, hospital discharge records, migration records and national diabetes registers were used, where available, to identify the study cohort and adjust for covariates. The study period start and end dates ranged respectively by dataset from 1 January 2000 to 1 July 2006 and from 31 December 2010 to 30 June 2011. The end date for the FIN dataset was brought forward by 6 months to December 2010 as cause of death data was not available after this point.
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Participants {#s2c}
------------

The study population comprised of patients with T2DM over the age of 40 whose therapy regimen was changed to include pioglitazone or any other antidiabetic medication during the study period. Potential cohort entry dates (CEDs) were identified as the date of the first ever pioglitazone prescription for pioglitazone-exposed patients and the date of switching to or add-on (initiation) of any other antidiabetic medication for the non-pioglitazone-exposed group. CEDs were excluded if there were \<12 months' membership in the medication database, any indication of bladder cancer prior to CED or if the patients were concurrently exposed to another thiazolidinedione.

Matching and covariates {#s2d}
-----------------------

Guidelines recommend a stepwise approach to the prescribing of antidiabetic drugs that consider the drug substance's efficacy in controlling blood glucose and its safety profile. Clinicians therefore 'channel' pioglitazone to patients at a specified stage of disease progression and with other characteristics that modify their prognosis. As stated in the previous manuscript, the following approach was taken in an attempt to eliminate channeling bias.[@R10]

Propensity scores (PS) were estimated for each CED using a weighted logistic regression model with weights reciprocal to the number of CEDs per individual. The PS model included baseline binary and categorical variables that were likely to have a direct impact on treatment choice and could be measured in all datasets. These included antidiabetic treatment immediately prior to CED, whether the treatment change at CED was an add-on or switch in therapy, use of thiazolidinediones (TZDs) prior to CED, duration of treated diabetes, number of different antidiabetic medications used prior to CED, history of MI, stroke, heart failure and the following diabetic complications: retinopathy or maculopathy, severe lower limb complications, renal complications, ketoacidosis, and hyperosmolar or ketoacidotic coma, duration of prescription database membership and calendar year of CED.

Pioglitazone CEDs were 1:1 fixed ratio matched and 1:10 variable ratio matched to non-pioglitazone CEDs using the PS distance and the following exact matching variables: antidiabetic treatment immediately prior to CED, whether the treatment change at CED was an add-on or switch in therapy and use of TZDs prior to CED. Non-pioglitazone-exposed patients were removed from further matching when one of their CEDs was matched to a pioglitazone-exposed patient. The number of matched non-pioglitazone-exposed patients varied between patients and countries in the 1:10 matched cohort, resulting in an imbalance in characteristics. The main analysis was therefore based on the 1:1 fixed ratio matched cohort. Each patient was followed up from CED until date of death or censorship due to end of membership of the database, end of database coverage, start of other TZDs or 30 June 2011. Time-varying (TV) covariates were generated to improve the estimation of adjusted HRs. The following binary and categorical TV covariates were generated for inclusion or testing in the regression model: use of each alternative antidiabetic treatment class, cumulative duration of exposure to insulin and diagnosis of bladder cancer. Use of antidiabetic treatment group other than pioglitazone and comorbidity history were categorized as ever versus never used and ever versus never occurred up to any given time period. Age categories were fixed at baseline.

Statistical analysis {#s2e}
--------------------

A pooled analysis was performed using the three datasets. Standardized differences were used to compare pioglitazone-exposed and never-exposed groups, with a score \<10 indicating good balance. Crude cause-specific mortality rates were estimated with 95% CI using Poisson regression. Cox proportional hazard models included as covariates age, gender, PS quintiles and TV use of antidiabetic medications. The proportional hazards assumption was examined by visually comparing the survival function for the pioglitazone-exposed and non-exposed groups. Further covariates, exact matching variables, PS variables and all variables that were included in the PS were included as confounders if their inclusion resulted in a minimum of 10% change in the HR of primary exposure (ever vs never exposed to pioglitazone) when introduced into the base model for the primary analysis for each cause-specific mortality outcome. Model selection was not repeated for stratified and sensitivity analyses. This differed from the all-cause mortality analyses in which exact matching and PS variables were automatically included in the adjusted model. History of chronic kidney disease/renal impairment, diabetic complications and macrovascular disease were added to previous stratified analyses for duration of treated diabetes at CED, use of other TZDs prior to CED and history of renal complications at CED. Sensitivity analyses assessing the results with respect to exposure and the inclusion of baseline smoking, baseline body mass index (BMI) and TV HbA1c as covariates were supplemented with post-hoc analyses adjusting for a log transformed continuous age variable, removing patients with prior stroke, MI or CHF at CED and country-specific analyses.

Further information {#s2f}
-------------------

Further details about the study methodology are published in the *BMJ* [@R4] and in the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) E-register of studies (study title 'Pan-European Multi-Database Bladder Cancer Risk Characterisation Study').

Results {#s3}
=======

The primary pooled matched cohort included 31 133 patients in both the pioglitazone-exposed and the non-exposed groups. This followed removal of all patients in the NL and UK GP datasets, and 1900 and 1 matched pairs from the FIN and UK GP-HOSP cohorts respectively due to lack of availability of cause-specific mortality data for one or both members of the pair. The three-country cohorts  are described in [table 1](#T1){ref-type="table"}. The number of antidiabetic treatments prescribed at CED was similar in both cohorts. The most commonly prescribed treatment regimens in the never exposed to pioglitazone group were insulin alone or in combination (37.5%), metformin and sulphonylureas (SU) in combination (22.1%), or combinations of other antidiabetic drugs (30.7%). Pioglitazone was prescribed in a variety of treatment regimens: most commonly in combination with metformin (36.7%) or metformin and SU (25.5%). Imbalance was observed in four of the variables used in the PS: MI or stroke at CED, CHF at CED, year of CED and duration of medication database membership prior to CED. The imbalance was due to reduced balance in key variables describing diabetic complications, history of macrovascular diseases and variables describing prior treatment in FIN (online [supplementary appendix tables 2a-c](#SP1){ref-type="supplementary-material"}).

###### 

Distribution of matching and non-matching covariates at cohort entry

  ----------------------------------------------------------------------------------------------------------------------------------------
                                                                   PIO exposed\           Non-PIO-exposed\       Standardized difference
                                                                   n=31 133 n (%)         n=31 133 n (%)         
  ---------------------------------------------------------------- ---------------------- ---------------------- -------------------------
  Dataset                                                                                                        

    FIN                                                            15 315 (49.19)         15 315 (49.19)         0.00

    SWE                                                            3712 (11.92)           3712 (11.92)           0.00

    UK GP-HOSP                                                     12 106 (38.88)         12 106 (38.88)         0.00

  Exact matching variables                                                                                       

   Type of treatment change at CED                                                                               

    Add-on                                                         18 774 (60.30)         18 774 (60.30)         0.00

    Switch                                                         12 359 (39.70)         12 359 (39.70)         0.00

   History of TZD at CED                                                                                         

    Never                                                          23 261 (74.71)         23 261 (74.71)         0.00

    Ever                                                           7872 (25.29)           7872 (25.29)           0.00

   Antidiabetic treatment immediately prior to CED\*                                                             

     Insulin (only or in combination)                              1456 (4.68)            1456 (4.68)            0.00

     Metformin and SU                                              7671 (24.64)           7671 (24.64)           0.00

     Metformin only                                                10 036 (32.24)         10 036 (32.24)         0.00

     No treatment                                                  3636 (11.68)           3636 (11.68)           0.00

     Other drugs or combination                                    5405 (17.36)           5405 (17.36)           0.00

     SU only                                                       2929 (9.41)            2929 (9.41)            0.00

  Propensity score variables                                                                                     

   Duration of treated diabetes at CED (years)                                                                   

    \<1                                                            3833 (12.31)           3870 (12.43)           0.36

     1 to \<2                                                      3923 (12.60)           3571 (11.47)           3.48

     2 to \<4                                                      6333 (20.34)           5957 (19.13)           3.03

     4 to \<6                                                      6379 (20.49)           7017 (22.54)           4.99

    ≥6                                                             10 665 (34.26)         10 718 (34.43)         0.36

     Range (min, max)                                              (0.00, 34.18)          (0.00, 24.79)          

     Mean (±SD)                                                    4.77 (3.61)            4.86 (3.62)            

     Median (Q1, Q3)                                               4.24 (1.80, 7.05)      4.43 (1.94, 7.02)      

   History of diabetic complications at CED                                                                      

    Diabetic retinopathy or maculopathy                            3189 (10.24)           3460 (11.11)           2.82

    Lower limb severe complications                                750 (2.41)             958 (3.08)             4.09

    Diabetic renal complications                                   2351 (7.55)            2452 (7.88)            1.22

    Ketoacidosis                                                   74 (0.24)              116 (0.37)             2.45

    Hyperosmolar/ketoacidotic coma                                 661 (2.12)             1097 (3.52)            8.46

   Other comorbidities at CED                                                                                    

    Myocardial infarction or stroke                                2687 (8.63)            3853 (12.38)           12.24

     Congestive heart failure                                      1069 (3.43)            2213 (7.11)            16.50

   Year at CED                                                                                                   

    2000--2003                                                     1672 (5.37)            4103 (13.18)           27.17

    2004--2007                                                     11 214 (36.02)         10 573 (33.96)         4.32

    2008--2011                                                     18 247 (58.61)         16 457 (52.86)         11.59

   Duration of medication database membership before CED (years)                                                 

     1--2                                                          2538 (8.15)            2528 (8.12)            0.12

     3--4                                                          2353 (7.56)            3184 (10.23)           9.39

     5--6                                                          3930 (12.62)           5912 (18.99)           17.52

     7+                                                            22 312 (71.67)         19 509 (62.66)         19.26

     Range (min, max)                                              (1.00, 22.00)          (1.00, 22.00)          

     Mean (±SD)                                                    8.86 (4.13)            8.37 (4.13)            

     Median (Q1, Q3)                                               9.00 (6.00, 11.00)     8.00 (5.00, 11.00)     

   Different antidiabetic drug classes ever prior to CED (n)                                                     

    0                                                              1097 (3.52)            1061 (3.41)            0.63

    1                                                              8928 (28.68)           7833 (25.16)           7.94

    2                                                              13 754 (44.18)         12 832 (41.22)         5.99

    3                                                              5833 (18.74)           7204 (23.14)           10.84

    \>3                                                            1521 (4.89)            2203 (7.08)            9.25

  Non-matching study variables (selected)                                                                        

   Age at CED (years)                                                                                            

     40--59                                                        12 073 (38.78)         9703 (31.17)           16.01

     60--69                                                        10 355 (33.26)         9506 (30.53)           5.85

    ≥70                                                            8705 (27.96)           11 924 (38.30)         22.10

     Range (min, max)                                              (40.00, 98.00)         (40.00, 101.00)        

     Mean (±SD)                                                    63.17 (10.68)          65.89 (11.53)          

     Median (Q1, Q3)                                               63.00 (56.00, 71.00)   66.00 (58.00, 75.00)   

   Sex                                                                                                           

     Male                                                          17 989 (57.78)         17 127 (55.01)         5.59

     Female                                                        13 144 (42.22)         14 006 (44.99)         5.59

   Different antidiabetic drug classes being used at CED† (n)                                                    

     1                                                             3242 (10.41)           4727 (15.18)           14.31

     2                                                             15 776 (50.67)         16 482 (52.94)         4.54

     3                                                             10 862 (34.89)         9494 (30.49)           9.38

    \>3                                                            1253 (4.02)            430 (1.38)             16.36

   Antidiabetic treatment at CED†                                                                                

    Insulin (only or in combination)                               1462 (4.70)            11 662 (37.46)         87.71

    Metformin and SU                                               7925 (25.46)           6872 (22.07)           7.95

    Metformin only                                                 11 439 (36.74)         2007 (6.45)            79.19

    No treatment                                                   3242 (10.41)           0 (0.00)               48.22

    Other drugs or combination                                     3830 (12.30)           9571 (30.74)           46.04

    SU only                                                        3235 (10.39)           1021 (3.28)            28.46

   Bladder comorbidities at CED                                                                                  

    Urinary incontinence                                           1941 (6.23)            2336 (7.50)            5.02

    Urinary tract infection                                        2458 (7.90)            2818 (9.05)            4.15

    Pyelonephritis                                                 458 (1.47)             604 (1.94)             3.62

    Urolithiasis                                                   809 (2.60)             723 (2.32)             1.78

    Hematuria                                                      1118 (3.59)            1192 (3.83)            1.26

    Urinary retention                                              369 (1.19)             530 (1.70)             4.34

    Neurogenic bladder                                             40 (0.13)              50 (0.16)              0.85

    Catheterization                                                321 (1.03)             450 (1.45)             3.75

   Other comorbidities at CED                                                                                    

    Other urinary tract cancer (excluding BC)                      96 (0.31)              105 (0:34)             0.51

    Other cancer (excluding urinary tract)                         3415 (10.97)           4078 (13.10)           6.55

    COPD                                                           2729 (8.77)            2959 (9.50)            2.56

   Use of other medications prior to CED                                                                         

    Statins                                                        14 933 (47.97)         13 832 (44.43)         7.10

    ARB                                                            9066 (29.12)           7856 (25.23)           8.74

    ACE inhibitors                                                 17 762 (57.05)         18 004 (57.83)         1.57

    BPH                                                            4108 (13.20)           4272 (13.72)           1.54
  ----------------------------------------------------------------------------------------------------------------------------------------

\*Treatments initiated at CED are not included.

†Treatments initiated at CED are included. For the PIO-exposed group, the listed treatments are in addition to PIO.

ARB, angiotensin receptor blockers; BC, bladder cancer; BPH, benign prostatic hypertrophy; CED, cohort entry date; COPD, chronic obstructive pulmonary disease;  FIN, Finland; PIO, pioglitazone; SU, sulphonylureas; SWE, Sweden; TZD, thiazolidinedione; UK GP-HOSP, UK linked dataset.

In country-specific analyses, notable differences were observed in a number of covariates. History of TZD at cohort entry, a fixed matching variable, was less common in FIN (17.3%) than in SWE (38.1%) or the UK (31.4%). Among the PS matching variables, diabetic complications were more common in the UK than in SWE and FIN. These differences were particularly pronounced for diabetic retinopathy or maculopathy (pioglitazone/non-pioglitazone): the UK 20.3%/19.1%; SWE 8.4%/8.3%; FIN 2.8%/5.5%; and diabetic renal complications: the UK 16.6%/16.3%; SWE 2.4%/1.9%; FIN 1.7%/2.7%. Full tables for each country are included in the online [supplementary appendix tables S2a to S4c](#SP1){ref-type="supplementary-material"}.

A total of 6176 deaths (1663 exposed and 4513 non-exposed) occurred during follow-up. This includes 2789 deaths due to CV-related causes (691 ever and 2098 never use of pioglitazone) and 3387 deaths due to non-CV causes (972 ever and 2415 never use of pioglitazone).

These events occurred over a mean 2.6 (SD 2.0) years of follow-up in the pioglitazone group and 2.7 (SD 2.3) in the non-pioglitazone-exposed group. The number of mortality events by ICD-10 chapter is provided in [table 2](#T2){ref-type="table"}. The most common causes of death were circulatory system-related deaths (45.9%) and neoplasms (26.5%).

###### 

Number and percentage of deaths by International Classification of Diseases, Tenth Revision (ICD-10) chapter

  Cause of death                                                         ICD-10 code   N (%)
  ---------------------------------------------------------------------- ------------- ----------------
  Total                                                                                6176 (100.00%)
  Circulatory system                                                     I00-I99       2834 (45.89%)
  Neoplasm                                                               C00 - D48     1635 (26.47%)
  Respiratory                                                            J00-J99       359 (5.81%)
  Endocrine, nutritional and metabolic                                   E00-E90       332 (5.38%)
  Digestive                                                              K00-K93       248 (4.02%)
  External cause                                                         V01-Y98       228 (3.69%)
  Nervous system                                                         G00-G99       179 (2.90%)
  Mental and behavioral                                                  F00-F99       144 (2.33%)
  Genitourinary                                                          N00-N99       85 (1.38%)
  Infectious disease                                                     A00-B99       55 (0.89%)
  Not classified elsewhere                                               R00-R99       28 (0.45%)
  Muscoskeletal and connective tissue                                    M00-M99       24 (0.39%)
  Skin and subcutaneous tissue                                           L00-L99       14 (0.23%)
  Blood, blood-forming organs and immune                                 D50-D89       7 (0.11%)
  Congenital malformations, deformations and chromosomal abnormalities   Q00-Q99       3 (0.05%)
  Eye and ear                                                            H00-H95       1 (0.02%)

CV versus non-CV mortality {#s3a}
--------------------------

The number of CV and non-CV events and their corresponding crude mortality rates are provided in [table 3](#T3){ref-type="table"}. The rate was lower in the pioglitazone-exposed group than the non-exposed group for both CV and non-CV mortality. The Kaplan-Meier curves for CV and non-CV mortality are consistent with the proportional hazards assumption ([figure 1A,B](#F1){ref-type="fig"}).

###### 

Number of cardiovascular and non-cardiovascular deaths and their corresponding crude mortality rates

                                PIO-exposed      Non-PIO-exposed
  ----------------------------- ---------------- -----------------
  Patients (n)                  31 333           31 333
  Patient years (mean, SD)      2.6 (2.0)        2.7 (2.3)
  Patient years (median, IQR)   2.3 (0.9--3.9)   2.1 (0.8--4.1)

                       Deaths (n)   Mortality rate per 10 000 patient-years (95% CI)   Deaths (n)   Mortality rate per 10 000 patient-years (95% CI)
  -------------------- ------------ -------------------------------------------------- ------------ --------------------------------------------------
  Cardiovascular       691          85.42 (79.28 to 92.03)                             2098         250.51 (240.02 to 261.46)
  Non-cardiovascular   972          120.15 (112.83 to 127.95)                          2415         288.36 (277.09 to 300.1)
  All-cause            1663         205.57 (195.92 to 215.69)                          4513         538.87 (523.38 to 554.82)

PIO, pioglitazone.

![Kaplan-Meier plots of association of exposure to pioglitazone with (A) cardiovascular (CV) mortality and (B) non-CV mortality in patients with type 2 diabetes. Ever, exposed to pioglitazone; Never, never exposed to pioglitazone.](bmjdrc-2017-000481f01){#F1}

The adjusted HR for ever exposed compared with never exposed to pioglitazone was 0.60 (95% CI 0.57 to 0.64) for all-cause mortality, 0.58 (95% CI 0.52 to 0.63) for CV mortality and 0.63 (95% CI 0.58 to 0.68) for non-CV mortality ([table 4](#T4){ref-type="table"}). No additional variables met the confounding inclusion criteria so the base model was considered the final model. All three HR estimates were statistically significant and indicated a decrease in the risk of mortality associated with pioglitazone exposure. The protective effect was strongest in the longest duration of exposure and highest cumulative dose categories ([table 4](#T4){ref-type="table"}). Discontinuation of pioglitazone use within the last year was associated with an increase in the mortality risk.

###### 

Adjusted\* HRs for cardiovascular (CV) mortality, non-CV mortality and all-cause mortality

  ---------------------------------------------------------------------------------------------------------------
  Exposure definitions                         CV mortality\         Non-CV mortality\     All-cause mortality\
                                               HR (95% CI)           HR (95% CI)           HR (95% CI)
  -------------------------------------------- --------------------- --------------------- ----------------------
  Pioglitazone exposure                                                                    

   Never                                       Reference             Reference             Reference

   Ever                                        0.58 (0.52 to 0.63)   0.63 (0.58 to 0.68)   0.60 (0.57 to 0.64)

  Pioglitazone current exposure                                                            

   No                                          Reference             Reference             Reference

   Yes                                         0.41 (0.36 to 0.47)   0.30 (0.26 to 0.34)   0.34 (0.31 to 0.38)

  Duration of pioglitazone exposure (months)                                               

   Never                                       Reference             Reference             Reference

   \<12                                        0.56 (0.50 to 0.63)   0.65 (0.58 to 0.71)   0.61 (0.56 to 0.66)

   12--24                                      0.64 (0.54 to 0.76)   0.61 (0.53 to 0.71)   0.62 (0.56 to 0.70)

   24--48                                      0.59 (0.49 to 0.71)   0.66 (0.57 to 0.78)   0.63 (0.56 to 0.71)

   \>48                                        0.44 (0.32 to 0.61)   0.45 (0.34 to 0.60)   0.44 (0.36 to 0.55)

  Cumulative pioglitazone dose (mg)                                                        

   Never                                       Reference             Reference             Reference

   1--10 500                                   0.57 (0.51 to 0.64)   0.64 (0.58 to 0.71)   0.61 (0.57 to 0.66)

   10 501--28 000                              0.63 (0.54 to 0.73)   0.66 (0.58 to 0.76)   0.64 (0.58 to 0.71)

   28 001--40 000                              0.54 (0.40 to 0.72)   0.62 (0.48 to 0.79)   0.58 (0.48 to 0.70)

   \>40 000                                    0.48 (0.36 to 0.66)   0.43 (0.32 to 0.57)   0.45 (0.37 to 0.55)

  Time since last exposure (years)                                                         

   Never                                       Reference             Reference             Reference

   Current use                                 0.38 (0.33 to 0.44)   0.30 (0.27 to 0.35)   0.34 (0.31 to 0.37)

   \<1                                         0.95 (0.81 to 1.10)   1.34 (1.20 to 1.50)   1.17 (1.07 to 1.28)

   1--2                                        0.61 (0.49 to 0.75)   0.75 (0.62 to 0.89)   0.68 (0.59 to 0.78)

   2--4                                        0.66 (0.53 to 0.80)   0.74 (0.62 to 0.89)   0.70 (0.61 to 0.80)

   \>4                                         0.77 (0.58 to 1.04)   0.71 (0.54 to 0.93)   0.73 (0.60 to 0.90)
  ---------------------------------------------------------------------------------------------------------------

\*Adjusted for dataset/country, propensity score quintiles, age at cohort entry dates, sex and ever exposed to metformin, sulphonylureas, insulin and other non-insulin diabetic treatments.

Significant interactions were observed in stratified analyses between pioglitazone exposure and the stratification variables ([table 5](#T5){ref-type="table"}). The reduced risk of all-cause, CV and non-CV mortality associated with pioglitazone use was stronger in patients with no history of diabetic complications, no history of macrovascular diseases and no history of chronic kidney disease or renal impairment. Duration of treated diabetes at CED, classified as \<4 years and ≥4 years, was not found to interact with the observed associations. The risk reduction for non-CV mortality was lower in patients with no history of other TZD use. There was a directional but not significant difference in the risk reduction for CV mortality in the ever versus never received TZD at cohort entry groups.

###### 

Adjusted HRs for all-cause, cardiovascular (CV) and non-CV mortality in each of the stratified analyses

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Strata (category A, category B)                                    Category A\           Category B\           P value for interaction test
                                                                     HR (95% CI)           HR (95% CI)           
  ------------------------------------------------------------------ --------------------- --------------------- ------------------------------
  CV mortality                                                                                                   

   Duration of treated diabetes (\<4, ≥4)                            0.59 (0.51 to 0.69)   0.54 (0.48 to 0.60)   0.687

   Use of other thiazolidinediones (never, ever)                     0.56 (0.51 to 0.62)   0.72 (0.55 to 0.94)   0.111

   History of diabetic complications (no, yes)                       0.52 (0.45 to 0.59)   0.63 (0.54 to 0.72)   0.002

   History of macrovascular disease (no, yes)                        0.50 (0.42 to 0.58)   0.63 (0.56 to 0.71)   \<0.001

   History of chronic kidney disease or renal impairment (no, yes)   0.52 (0.47 to 0.58)   0.72 (0.60 to 0.87)   0.008

  Non-CV mortality                                                                                               

   Duration of treated diabetes (\<4, ≥4)                            0.64 (0.57 to 0.72)   0.63 (0.56 to 0.70)   0.339

   Use of other thiazolidinediones (never, ever)                     0.60 (0.55 to 0.65)   0.86 (0.69 to 1.08)   0.004

   History of diabetic complications (no, yes)                       0.57 (0.51 to 0.63)   0.69 (0.61 to 0.78)   0.004

   History of macrovascular disease (no, yes)                        0.58 (0.52 to 0.64)   0.70 (0.62 to 0.80)   \<0.001

   History of chronic kidney disease or renal impairment (no, yes)   0.58 (0.52 to 0.63)   0.75 (0.64 to 0.89)   0.013

  All-cause mortality                                                                                            

   Duration of treated diabetes (\<4, ≥4)                            0.62 (0.56 to 0.68)   0.58 (0.53 to 0.63)   0.836

   Use of other thiazolidinediones (never, ever)                     0.58 (0.54 to 0.62)   0.80 (0.67 to 0.95)   0.001

   History of diabetic complications (no, yes)                       0.54 (0.5 to 0.59)    0.66 (0.60 to 0.72)   \<0.001

   History of macrovascular disease (no, yes)                        0.55 (0.5 to 0.6)     0.66 (0.61 to 0.72)   \<0.001

   History of chronic kidney disease or renal impairment (no, yes)   0.55 (0.51 to 0.59)   0.74 (0.65 to 0.84)   \<0.001
  ---------------------------------------------------------------------------------------------------------------------------------------------

A statistically significant reduction in mortality risk was observed in all stratified analyses ([table 5](#T5){ref-type="table"}) with the exception of use of TZDs prior to cohort entry for non-CV mortality (HR 0.86, 95% CI 0.69, 1.08) and sensitivity analyses (online [supplementary appendix tables S5a and S5b](#SP1){ref-type="supplementary-material"}). These included country-specific analyses ([table 6](#T6){ref-type="table"}). For CV-specific mortality, relative risk reduction ranged from 7% in the UK GP-HOSP dataset to 65% in SWE. For non-CV mortality, the range was from 17% in SWE to 51% in FIN. In FIN and UK GP-HOSP, the HR for CV mortality is similar to the HR for non-CV mortality. There was a considerable difference between the HRs in SWE where the protective effect was strongest for CV mortality.

###### 

Adjusted HRs for all-cause, cardiovascular (CV) and non-CV mortality in each dataset

  ----------------------------------------------------------------------------------------
  Sensitivity analysis   CV mortality\         Non-CV mortality\     All-cause\
                         HR (95% CI)           HR (95% CI)           HR (95% CI)
  ---------------------- --------------------- --------------------- ---------------------
  FIN                    0.46 (0.41 to 0.53)   0.49 (0.44 to 0.55)   0.48 (0.44 to 0.52)

  SWE                    0.35 (0.22 to 0.56)   0.83 (0.62 to 1.10)   0.63 (0.49 to 0.80)

  UK GP-HOSP             0.93 (0.79 to 1.09)   0.82 (0.72 to 0.94)   0.86 (0.78 to 0.95)

  Pooled data            0.58 (0.52 to 0.63)   0.63 (0.58 to 0.68)   0.60 (0.57 to 0.64)
  ----------------------------------------------------------------------------------------

FIN, Finland; SWE, Sweden; UK GP-HOSP, UK linked dataset.

CV mortality subanalyses {#s3b}
------------------------

The most common CV cause of death in each group was MI followed by stroke and heart failure. Together these accounted for 88% of CV deaths in both the pioglitazone-exposed and non-exposed group. The crude mortality rate was lower in the pioglitazone-exposed group than the non-exposed group for each CV cause ([table 7](#T7){ref-type="table"}).

###### 

Number of cardiovascular cause-specific deaths and their corresponding crude mortality rates per 10 000 person-years

  -----------------------------------------------------------------------------------------------------------------------------------------------
                                              Ever exposed to pioglitazone\   Never exposed to pioglitazone\          
                                              n=31 133                        n=31 133                                
  ------------------------------------------- ------------------------------- -------------------------------- ------ ---------------------------
  Myocardial infarction                       467                             57.73 (52.72 to 63.21)           1380   164.78 (156.31 to 173.71)

  Stroke                                      92                              11.37 (9.27 to 13.95)            340    40.6 (36.5 to 45.15)

  Heart failure                               47                              5.81 (4.37 to 7.73)              132    15.76 (13.29 to 18.69)

  Peripheral vascular disease                 15                              1.85 (1.12 to 3.08)              33     3.94 (2.8 to 5.54)

  Arrhythmia                                  9                               1.11 (0.58 to 2.14)              42     5.01 (3.71 to 6.79)

  Renovascular disease                        1                               0.12 (0.02 to 0.88)              12     1.43 (0.81 to 2.52)

  Sudden death\*                              0                                                                2      

  Other cardiovascular diseases of interest   60                              7.42 (5.76 to 9.55)              157    18.75 (16.03 to 21.92)
  -----------------------------------------------------------------------------------------------------------------------------------------------

\*Mortality not calculated due to lack of statistical convergence of the model.

The adjusted HRs for MI, stroke and heart failure were 0.61 (95% CI 0.55 to 0.69), 0.48 (95% CI 0.38 to 0.62) and 0.60 (95% CI 0.42 to 0.86), respectively. A decreased risk of mortality was observed for all CV causes with statistical significance demonstrated in all except renovascular disease and peripheral vascular disease ([figure 2](#F2){ref-type="fig"}). There were no clear trends with increasing duration of pioglitazone use or with increasing cumulative dose (online [supplementary appendix table S6](#SP1){ref-type="supplementary-material"}).

![Adjusted HRs with 95% CI for the association between pioglitazone use and cause-specific mortality. CVD, cardiovascular disease.](bmjdrc-2017-000481f02){#F2}

Preplanned stratified analyses were restricted to MI and stroke due to low numbers of deaths in other categories (online [supplementary appendix table S7a and S7b](#SP1){ref-type="supplementary-material"}). The reduced risk of MI-related mortality associated with pioglitazone use was stronger in patients with no history of macrovascular diseases and for patients with no history of diabetic complications. Stratified analyses for stroke-related mortality were consistent with the main findings. Sensitivity analyses completed for MI, stroke and heart failure demonstrated a directional or statistically significant protective effect of pioglitazone in all analyses with the exception of MI in the UK (HR 1.05, 95% CI 0.86 to 1.28) (online [supplementary appendix tables S8a and S8b](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

In this post-hoc analysis using a large three-country European cohort of patients with T2DM, we found a statistically significant 42% and 37% reduction in risk of CV and non-CV mortality, respectively, in patients whose antidiabetic therapy was modified to include pioglitazone compared with an alternative antidiabetic medication at a similar stage of disease progression. Comparators included a full range of antidiabetic treatment regimens from metformin alone (6%) to insulin used alone or in combination (37%). We also observed a statistically significant 39%, 52% and 40% reduction for MI, stroke and heart failure cause-specific mortality.

There was no evidence of a consistent trend in mortality risk (CV or non-CV) with increasing duration of pioglitazone use or with increasing cumulative dose of pioglitazone. Discontinuation of exposure to pioglitazone within the last year was associated with an increase in the mortality risk. This may be due to switch to insulin therapy for end-stage patients or undocumented pioglitazone treatment during hospitalization that could be missing in drug prescription/dispensing registers.

Strengths of the primary study[@R4] include the large number of patients included in the study, long follow-up period (up to 10 years) and extensive measures to reduce or investigate potential biases. These include a PS matched cohort design to minimize channeling bias related to factors that were hypothesized to influence prescribing decisions and be associated with the bladder cancer outcome, which was the outcome of interest in the main pan-European study. This resulted in the pioglitazone-exposed groups in the matched cohort for the bladder cancer analysis being balanced with regards to the distribution of measured confounders included as exact matching variables or in the PS. Marginal exceptions included CHF at baseline, early cohort entry (2000--2003) and higher duration of medication database membership before CED (5--6 and 7+years), where the standardized differences marginally exceeded 10. The design included further adjustment for matching variables and additional baseline and TV confounders in the main regression model. We also ran numerous stratifications to identify potential effect modification and sensitivity analyses to evaluate robustness of study results. These included an assessment of the impact of BMI, smoking status and TV HbA1c as covariates in countries where these variables were available. Remaining limitations were the potential for residual confounding due to unmeasured covariates such as general health and socioeconomic status[@R11]; and left truncation of prescribing data, particularly in SWE where data collection started in July 2005.[@R4] This left truncation may have led to misclassification of incident pioglitazone exposure despite the requirement for at least 1 year of baseline data prior to index.

These strengths and limitations broadly apply to this extended analysis as well. However, the covariates and likely mechanisms through which they influence the association between pioglitazone exposure and outcomes differ for bladder cancer and specific causes of mortality. For example, urinary tract or other cancers diagnosed either prior to baseline or developing during follow-up were not found to be significant confounders in the primary analyses for each cause-specific mortality outcome and therefore not included in the final models. In a study designed specifically to test the association of pioglitazone use with all cancers, patients diagnosed with cancer prior to baseline would likely be removed. There is also a potential risk that residual confounders such as general health and severity of pre-existing conditions have a stronger impact on the association between pioglitazone use and cause-specific mortality and may partially contribute to the observed association. Conversely, there is an increased risk that covariates included in the PS model were not associated with the mortality outcomes. In order to minimize the effect of this, exact matching and individual PS variables were not automatically included in the adjusted models in the analyses reported here. They were tested as confounders using a stepwise methodology but did not meet the threshold for inclusion in the final model. This change in approach decreased the effect size for all-cause mortality from 25% reported in the all-cause mortality manuscript[@R5] to 14% in the UK-HOSP dataset. In FIN, we observed an increase in effect from 46% to 52% which could be due to one or both of this change in methodology or the loss of matched pairs with CEDs in 2011 and resulting loss of covariate balance in multiple PS covariates, notably MI or stroke at baseline, CHF at baseline, year of CED and duration of medication database membership prior to CED. There was no change in SWE.

CV and non-CV mortality risk reductions were observed in all countries. In SWE, this reduction was statistically significant for CV mortality risk (HR 0.35, 95% CI 0.22 to 0.56) but smaller and directional for non-CV mortality risk (HR 0.83, 95% CI 0.62 to 1.10). Similar differences between CV and non-CV mortality risk were not observed in FIN and the UK, although both effect sizes were larger in FIN and the risk reduction for CV mortality risk was not significant in the UK.

Stratified analyses demonstrated statistically significant effect modification by history of diabetic complications, chronic kidney disease and macrovascular disease for both CV and non-CV mortality, with a weaker risk reduction associated with pioglitazone use in patients with a history of these conditions. Diabetic complications and renal disease were more common in the UK than in SWE and FIN. The reduced risk of both CV and non-CV mortality was weaker in the UK sensitivity analysis. Given the use of primary care data in the UK in addition to the secondary care data sources used in all three countries, these differences may in part reflect differences in data recording. This may lead to variation in PS modeling and matching with the UK model better able to minimize channeling bias. Conversely misclassification of exposure may be higher in the UK where analyses rely on prescribing data than in FIN and SWE where dispensing data were used. Assuming that misclassification was non-differential, this would attenuate the observed protective effect in the UK. Country differences may also reflect true differences in diabetic complications and renal disease attenuating the beneficial effect of pioglitazone or differences in other characteristics and care received by patients prescribed pioglitazone in the three countries. Cause of death registers in all three countries use WHO ICD-10 to code underlying cause of death and follow internationally agreed rules.[@R12] Differential coding of cause of death between countries and between pioglitazone-exposed and unexposed groups is therefore unlikely.

Stratified analyses for history of TZD at cohort entry showed a stronger protective effect with pioglitazone use in patients with no history of TZD use for non-CV mortality where the effect was statistically significant and CV mortality where the effect was directional. For CV mortality, this risk difference may be explained by the propensity of rosiglitazone to increase CV risk which led to its withdrawal from the UK market in 2010.[@R11] Interestingly, history of TZD use at cohort entry was less common in FIN than in SWE and the UK and the risk reduction for non-CV mortality was greater in the FIN sensitivity analysis.

Liao *et al* recently published a meta-analysis of nine randomized controlled trials evaluating the effect of pioglitazone on CV and safety outcomes. This meta-analysis demonstrated a significantly reduced risk of major CV events (composite of non-fatal MI, non-fatal stroke and CV death) in patients with diabetes (relative risk (RR) 0.83, 95% CI 0.72 to 0.97) and pre-diabetes or insulin resistance (RR 0.77, 95% CI 0.64 to 0.93).[@R8] This is in line with our finding of a protective effect for pioglitazone on CV mortality compared with other antidiabetic treatments prescribed at similar stage of disease progression. The meta-analysis also demonstrated an increased risk of CHF with pioglitazone (RR 1.32; CI 1.14 to 1.54). This contradicts our findings of a protective effect for CHF mortality (HR 0.60, 95% CI 0.42 to 0.86), perhaps reflecting adherence to warnings about the safety of pioglitazone prescribing in patients with heart failure when used in the real-world setting, following publication of the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) randomized control trial.[@R9]

There is little evidence from randomized controlled trials and observational studies examining the association of pioglitazone with non-CV patient outcomes and mortality with which to compare findings from this study. However, no statistically significant difference was observed in the rate of all-cause mortality in Liao *et al*'s meta-analysis (seven trials; RR 0.93, 95% CI 0.80 to 1.09).[@R8] The vast majority (90%) of the 11 319 subjects in the meta-analysis were enrolled in two large trials: the PROactive[@R16] trial in patients with type 2 diabetes at high risk of CV disease and the Insulin Resistance Intervention after Stroke (IRIS) trial in pre-diabetic patients with a history of ischemic stroke or transient ischemic attack. The result from the meta-analysis contradicts the findings from the current analysis and other large observational studies with long follow-up periods that have demonstrated significant reductions in all-cause mortality risk with pioglitazone use over longer follow-up periods.[@R5] This lack of agreement is likely to be due to a combination of reduced statistical power in randomized control trials designed primarily to study CV and composite outcomes, residual bias in observational studies primarily designed to study cancer outcomes and differences between the characteristics of patients enrolled or included in the studies.

Cancer was assessed as a safety outcome in Liao *et al*'s meta-analysis in which a directional protective effect was observed (four trials; RR 0.91, CI 0.77 to 1.08).[@R8] Suggested mechanisms for CV and non-CV benefits of pioglitazone, based on preclinical and clinical studies, include improvements in insulin resistance, decreased hyperglycemia, fat redistribution, renoprotection and improved liver function.[@R9] A protective effect of pioglitazone for non-CV mortality is therefore plausible. Further research is required in this area before conclusions can be drawn.

Conclusions {#s4a}
-----------

This extended analysis following a large, observational multidatabase European cohort study found that prescribing pioglitazone compared with an alternative treatment decision at a similar stage of disease progression was associated with a reduction in both CV and non-CV mortality. Further observational and prospective studies that are specifically designed to test the association between pioglitazone use and patient-focused outcomes such as cause-specific mortality are suggested. Observational study designs should consider the nature of prescribing over time in the countries of interest and effect modification by prior TZD prescribing, history of diabetic complications and history of macrovascular disease.
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